2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
7
Skin Neoplasms
4
Carcinoma, Squamous Cell
3
Recurrence
2
Dermatofibrosarcoma
2
Surgical Wound
1
Postoperative Complications
1
Nonmelanoma Skin Cancer
1
Neoplasms, Adnexal and Skin Appendage
1
Melanoma
1
Hutchinson's Melanotic Freckle
1
Histiocytoma, Malignant Fibrous
1
Eyelid Neoplasms
1
Cicatrix
1
Adenocarcinoma, Sebaceous
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
136
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
68
fludarabine phosphate
62
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Specimen Handling
36
Cisplatin
36
CTLA-4 Antigen
36
Magnetic Resonance Spectroscopy
35
Carboplatin
35
cobimetinib
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Mohs Surgery
×
Clear all
NCT02310503
2020-05-05
REGESMOHS
Fundación Academia Española de Dermatología
Completed
6,000 enrolled